|
Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.
|
 |
|
The company says its siRNA-based approach could spare lean muscle at an infrequent dosing schedule as obesity outcomes are defined by more than just weight loss.
|
|
|
The UK remains competitive in its science, but experts say more must be done to incentivise investment into Britain as global rivalry mounts.
|
|
|
Quoin has now received two rare paediatric disease designations for its lead asset QRX003.
|
|
|
The designation was based on preliminary clinical evidence from the ongoing SPRINX-1 Phase I/IIa study.
|
|
|
The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.
|
|
